Adenosine Receptors in Neurology and Psychiatry
- 1st Edition, Volume 119 - September 2, 2014
- Latest edition
- Editor: Akihisa Mori
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 0 1 0 2 2 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 0 1 3 1 8 - 2
This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume co… Read more
This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on adenosine receptor science, providing insights useful for actual drug discovery/development in neurology and psychiatry areas.
- Expertise of contributors
- Subject including practical drug development from basic science, as translational research taste
- Structure of contents focusing on two CNS areas for diseases (neurology and psychiatry)
People working for: basic neuroscience, purinergic science, neurology and psychiatry; investors and businesses in pharmaceutical R&D; medical doctors and care givers.
- Preface
- Chapter One: Adenosine Receptor Neurobiology: Overview
- Abstract
- 1 General Introduction
- 2 Source and Regulation of Extracellular Adenosine Level
- 3 ARs Subtypes: Classification and Gene Structures
- 4 Expression of ARs in the Brain
- 5 Structure Biology of Adenosine A2A Receptors
- 6 Canonical and Noncanonical Signaling Pathways of ARs
- 7 Interactions Between ARs and Other GPCRs and Neurotrophic Factor Receptors
- 8 AR Functions: Insights from Pharmacological and Genetic-KO Approaches
- 9 ARs and Glial Functions
- 10 Pathophysiological Functions of ARs
- 11 ARs as Drug Targets
- Acknowledgments
- Chapter Two: Adenosine Receptor PET Imaging in Human Brain
- Abstract
- 1 Introduction
- 2 PET Imaging of Adenosine A1 Receptors
- 3 PET Imaging of Adenosine A2A Receptors
- 4 Conclusions
- Chapter Three: An Overview of Adenosine A2A Receptor Antagonists in Parkinson's Disease
- Abstract
- 1 Problems in the Treatment of Parkinson's Disease
- 2 Non-dopaminergic Approaches to the Treatment of PD
- 3 Adenosine A2A Receptor Antagonists and Motor Function
- 4 Adenosine A2A Receptor Antagonists and Nonmotor Symptoms of PD
- 5 A2A Adenosine Receptor Antagonists and Neuroprotection in PD
- 6 A2A Receptor Antagonists and Clinical Outcomes in PD
- 7 Conclusions
- Chapter Four: Mode of Action of Adenosine A2A Receptor Antagonists as Symptomatic Treatment for Parkinson's Disease
- Abstract
- 1 Introduction
- 2 The Basal Ganglia–Thalamocortical Circuit and Pathophysiology of PD
- 3 Striatal MSNs
- 4 Localization of Adenosine A2A Receptors On/Around Striatal MSNs
- 5 Proposed Mechanism of Adenosine A2A Receptor Function and Mode of Action of A2A Receptor Antagonists on Motor Control via the Basal Ganglia
- 6 New Aspect for the Pathophysiological Change to Striatopallidal MSNs in PD
- 7 Concluding Remarks
- Chapter Five: Adenosine Receptors and Dyskinesia in Pathophysiology
- Abstract
- 1 Pathogenesis of Levodopa-Induced Dyskinesia
- 2 Adenosine A2A Receptors and Levodopa-Induced Dyskinesia
- Chapter Six: Clinical/Pharmacological Aspect of Adenosine A2A Receptor Antagonist for Dyskinesia
- Abstract
- 1 Introduction
- 2 Nonclinical Studies of the Effects of Adenosine A2A Receptor Antagonists on Dyskinesia
- 3 Clinical Outcomes of Adenosine A2A Receptor Antagonist on Dyskinesia
- 4 Comparison Between Nonclinical and Clinical Findings on Adenosine A2A Receptor Blockade and Dyskinesia
- 5 Conclusions
- Chapter Seven: Interaction of Adenosine Receptors with Other Receptors from Therapeutic Perspective in Parkinson's Disease
- Abstract
- 1 Introduction
- 2 Adenosine Receptors in the Basal Ganglia and Signal Transduction
- 3 A1 and A2A Adenosine Receptor Interactions and Heterodimerization
- 4 Adenosine and Dopamine Receptor Interactions and Heterodimerization
- 5 Adenosine and Glutamate Receptor Interactions and Heterodimerization
- 6 Discussion
- 7 Conclusion
- Acknowledgments
- Chapter Eight: Effects of the Adenosine A2A Receptor Antagonist on Cognitive Dysfunction in Parkinson's Disease
- Abstract
- 1 Introduction
- 2 Cognitive Dysfunction in PD
- 3 The Role of Adenosine A2A Receptors on Cognitive Function
- 4 Effects of Adenosine A2A Receptor Antagonists on Cognitive Dysfunction in PD
- 5 Conclusion
- Chapter Nine: Clinical Nonmotor Aspect of A2A Antagonist in PD Treatment
- Abstract
- 1 Introduction
- 2 Case Report
- 3 Discussion
- 4 Conclusion
- Chapter Ten: Adenosine Receptors and Huntington's Disease
- Abstract
- 1 Pathogenetic Mechanisms of Huntington's Disease
- 2 Alteration in Adenosine Homeostasis in HD
- 3 Regulation of Adenosine Receptors in HD
- 4 Therapeutic Actions of Adenosine Receptor Agonists and Antagonists in HD
- 5 Positron Emission Tomography Imaging for Adenosine Receptor Occupancy in HD
- 6 Concluding Remarks
- Acknowledgments
- Chapter Eleven: Adenosine Receptors and Epilepsy: Current Evidence and Future Potential
- Abstract
- 1 Introduction
- 2 Adenosine Regulates Ongoing Neurotransmission
- 3 Adenosine Receptor Subtypes and Epilepsy
- 4 Chronic Changes in Adenosine Receptor Activation
- 5 Gliosis, Adenosine Kinase, and Epileptogenesis
- 6 Human Adenosine Receptor Polymorphisms
- 7 Adenosine and Neuroinflammation
- 8 Adenosine-Based Mechanisms Underlying Anticonvulsant Diet Therapy
- 9 Conclusions
- Chapter Twelve: Adenosine Receptor Control of Cognition in Normal and Disease
- Abstract
- 1 Adenosine as an Upstream Regulator of Dopamine, Glutamate, and Brain-Derived Neurotrophic Factor Signaling: A Molecular Basis for AR Control of Cognition
- 2 Adenosine Receptor Modulation of Synaptic Plasticity: A Cellular Basis for AR Control of Cognition
- 3 Adenosine Receptor Modulates Learning and Memory in Normal Animals
- 4 Adenosine Receptor Control of Cognition in Neuropsychiatric Disorders
- 5 Concluding Remarks
- Acknowledgments
- Chapter Thirteen: Adenosine Receptors in Cerebral Ischemia
- Abstract
- 1 Introduction
- 2 A1 Receptors in Brain Ischemia
- 3 A2A Receptors in Brain Ischemia
- 4 A2B Receptors in Brain Ischemia
- 5 A3 Receptors in Brain Ischemia
- 6 Conclusions
- Chapter Fourteen: Roles of Adenosine and Its Receptors in Sleep–Wake Regulation
- Abstract
- 1 Introduction
- 2 Formation, Metabolism, and Transport of Adenosine in the Central Nervous System
- 3 Adenosine Is a Key Signaling Molecule for PGD2-Induced Sleep
- 4 An Increase in the Extracellular Adenosine Level Promotes Sleep
- 5 Predominant Roles of A2A Receptor in Sleep Regulation
- 6 The Involvement of A2A Receptor in the NAc in Sleep–Wake Regulation
- 7 A1 Receptors Contribute to Sleep Induction in a Region-Dependent Manner
- 8 Conclusions
- Acknowledgments
- Chapter Fifteen: Involvement of Adenosine A2A Receptors in Depression and Anxiety
- Abstract
- 1 Introduction
- 2 Adenosine Receptors and Anxiety
- 3 Adenosine Receptors and Depression
- 4 Mechanisms of Actions After the Blockade of Adenosine A2A Receptors
- 5 Conclusion
- Chapter Sixteen: The Adenosine Neuromodulation System in Schizophrenia
- Abstract
- 1 Clinical Features of Schizophrenia
- 2 Morphological and Neurochemical Features of Schizophrenia
- 3 The Adenosine Neuromodulation System
- 4 Impact of Manipulating the Adenosine System in Animal Models of Schizophrenia
- 5 Impact of Caffeine and Other Drugs Acting on the Adenosine Modulation System in Schizophrenic Patients
- 6 Proposed Adenosine Hypothesis of Schizophrenia
- Acknowledgments
- Author Index
- Contents of Recent Volumes
- Edition: 1
- Latest edition
- Volume: 119
- Published: September 2, 2014
- Language: English
AM
Akihisa Mori
Akihisa Mori, PhD., Deputy Director, Strategic Product Portfolio Department, Kyowa Hakko Kirin Co., Ltd. Tokyo, Japan. He has been leading adenosine A2A receptor science, intensively and extensively researching and discovering physiological functions of adenosine A2A receptor for brain motor control, and through such a tremendous scientific work, has also been working for a first-in-class Adenosine A2A receptor antagonist as new medication for Parkinson’s Disease, for more than 20 years, from its discovery stage to filing both US and Japan NDA, which has been launched in Japan (2013). He was graduated from Faculty of Pharmaceutical Sciences, Kyoto University in 1985, and obtained Ph.D. degree from Graduate School of Medicine and Faculty of Medicine, The University of Tokyo in 1996. With number of publications in peer review journals in neuroscience field (e.g., J. Neuroscience, Neurology, J. Physiology, Annals of Neurology, British J Pharmacology etc.), he has given more than 20 lectures/podium talks for academia/universities and international conferences on various subjects (e.g., neurophysiology, adenosine receptor science, Parkinson’s Disease, global drug development etc.) held not only in Japan but also in UK, Germany, Australia, Austria, and USA. In summary, he has greatly been contributing to translate from basic science of adenosine biology to practical drug development for adenosine receptor ligand in neurology area.
Affiliations and expertise
Kyowa Hakko Kirin Co., Ltd, JapanRead Adenosine Receptors in Neurology and Psychiatry on ScienceDirect